Bedrijfsoverzicht
Sana Biotechnology, Inc. is a biotechnology enterprise dedicated to the development of engineered cells utilized as therapeutic medicines within the United States market. The company specializes in creating both ex vivo and in vivo cell engineering platforms designed to address unmet treatment needs in specific therapeutic areas, such as type 1 diabetes and B cell mediated autoimmune diseases. Operating within the broader Healthcare sector and the specific Biotechnology industry, the firm targets patients requiring advanced cellular therapies where traditional treatments may be insufficient. The company's current market capitalization stands at $824.62M, supported by a workforce of 142 employees, while reported annual revenue is not disclosed in available public filings. The absence of disclosed revenue figures alongside a market cap of $824.62M suggests the company is likely in a pre-revenue or early-stage revenue generation phase typical for many biotechnology firms focused on novel cell engineering technologies. This valuation places the company in a niche segment of the healthcare market where value is often driven by pipeline potential rather than current earnings, distinguishing it from mature pharmaceutical entities with established sales streams.
Financiële gezondheid
The company reports a net income of $-244,166,000 over the trailing twelve months, while EBITDA is recorded at $-178,208,000, indicating a significant loss-making trajectory. Since the revenue figure is not available in the current data, the substantial gap between the reported net income and the implied revenue structure reveals a cost base heavily weighted toward research, development, and operational expenses common in the biotechnology sector. Free cash flow stands at $-53,566,752, which indicates that the company is currently consuming cash reserves to fund its operations and clinical trial activities rather than generating surplus liquidity. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, reflecting a standard characteristic for early-stage biotechnology companies where revenue recognition has not yet covered the high fixed costs of product development. Despite the negative earnings, the company maintains a cash balance of $138.38M against total debt of $86.26M, resulting in a debt-to-equity ratio of 53.62 which suggests a leveraged balance sheet typical for capital-intensive industries. The current ratio of 1.89 indicates that the company possesses sufficient liquid assets to cover its short-term liabilities nearly twice over, providing a buffer against immediate liquidity pressures. Furthermore, the return on equity is -118.7% and the return on assets is -26.0%, metrics that reveal that management is currently deploying capital to expand the business rather than generating immediate shareholder returns, a strategy inherent to companies in the developmental stage of their technology lifecycle.
Waarderingsbeoordeling
The trailing twelve months P/E ratio is not available due to negative earnings, while the forward P/E ratio is listed at -5.06, implying that the market anticipates the company will continue to report negative earnings in the near future. The price-to-book ratio stands at 5.12, indicating that the market values the company at more than five times its net asset value, which often reflects the high intangible value of intellectual property and pipeline assets held by biotechnology firms. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA of -4.33 are also not available or negative, further highlighting the reliance on non-traditional valuation methods for pre-profitability biotechnology companies. The stock has experienced significant volatility over the past year, trading between a 52-week high of $6.55 and a 52-week low of $1.53. Without a specific current share price provided in the source data to calculate the exact percentage difference, the trading range demonstrates a wide dispersion typical of high-beta biotech stocks. The beta value of 2.06 indicates that the stock price is expected to be highly volatile, moving with twice the magnitude of the broader market, which necessitates a higher risk premium from investors.
Growth & Income
Revenue growth and earnings growth rates over the year-over-year period are not available in the provided financial data, preventing a direct comparison of earnings growth relative to revenue expansion. Consequently, it is not possible to determine if earnings are growing faster or slower than revenue based on the current dataset, though the negative earnings suggest the company is still investing heavily rather than optimizing profitability. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm reinvests all available resources and potential earnings back into research, development, and clinical trials. This absence of a dividend policy confirms that the company's growth strategy relies entirely on capital appreciation and the eventual commercial success of its engineered cell therapies rather than income distribution. The overall growth and income profile is characterized by a high-risk, high-reward dynamic where current financial metrics reflect significant investment in future therapeutic potential rather than immediate financial performance or shareholder income generation.